Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows (unaudited)

v3.22.0.1
Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Activities:      
Consolidated net income (loss) $ 46,082 $ (17,282) $ (101,282)
Adjustments to reconcile consolidated net income (loss) to cash provided by (used in) operating activities:      
Depreciation expense 23,292 30,268 47,909
Asset impairments 3,100 24,356 29,292
Income from loan forgiveness (9,860)
Fair value adjustments 9,959  
Gain on sale of assets (4,571) (1,580)  
Loss on debt extinguishment 6,517
Inventory valuation   (257)  
Gains on derivative instruments (21,619) (14,780) (555)
Amortization of deferred financing costs 778 1,394 511
Amortization of debt discounts (premiums) (230) (230) 689
Noncash compensation 2,883 2,679 2,809
Bad debt expense 158 245 27
Interest expense added to senior notes 133 1,185
Changes in operating assets and liabilities:      
Accounts receivable (43,554) 30,571 (6,698)
Inventories (16,448) 19,090 (2,780)
Other current assets 38,989 1,507 3,895
Operating leases (4,216) (4,751) (10,161)
Assets held-for-sale (3,483) 1,012  
Liabilities held-for-sale 2,305 9,110  
Accounts payable and accrued expenses 13,215 (19,763) (2,585)
Net cash provided by (used in) operating activities 26,821 71,681 (31,227)
Investing Activities:      
Proceeds from sale of Stockton 24,000    
Proceeds from sale of Madera 19,500  
Proceeds from sale of interests in PAL 19,896  
Proceeds from Magic Valley asset sale   10,000  
Additions to property and equipment (16,384) (6,580) (3,281)
Net cash provided by (used in) investing activities 27,116 23,316 (3,281)
Financing Activities:      
Proceeds from issuances of common stock and warrants 462 75,829 3,670
Proceeds from warrant exercises 5,500  
Proceeds from CARES Act loans 9,860  
Net proceeds (payments) on Kinergy’s line of credit 17,889 (45,826) 21,282
Payments on plant borrowings (29,964) (71,536) (8,000)
Payments on senior notes (25,533) (40,249) (3,748)
Preferred stock dividend payments (2,853) (946)
Proceeds from CoGen contract amendment 8,036
Debt issuance costs (1,280)
Net cash provided by (used in) financing activities (39,999) (66,422) 19,014
Net increase (decrease) in cash, cash equivalents and restricted cash 13,938 28,575 (15,494)
Cash, cash equivalents and restricted cash at beginning of period 48,187 19,612 35,106
Cash, cash equivalents and restricted cash at end of period 62,125 48,187 19,612
Reconciliation of total cash, cash equivalents and restricted cash:      
Cash and cash equivalents 50,612 47,667 18,997
Restricted cash 11,513 520 615
Total cash, cash equivalents and restricted cash 62,125 48,187 19,612
Supplemental Information:      
Interest paid (net of capitalized interest) 3,489 17,469 18,763
Capitalized interest 628 224 563
Income tax (payments) refunds (448) 641
Noncash financing and investing activities:      
Initial right of use assets and liabilities recorded under ASC 842 43,753
Issuance of common stock for senior note amendment 3,817
Issuance of warrants for senior note amendment 977
Accrued preferred stock dividends   $ 1,268 $ 319